Ancora Advisors LLC lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 2.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,003 shares of the medical research company’s stock after acquiring an additional 509 shares during the quarter. Ancora Advisors LLC’s holdings in Amgen were worth $4,769,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Alps Advisors Inc. grew its holdings in shares of Amgen by 10.4% in the 2nd quarter. Alps Advisors Inc. now owns 5,525 shares of the medical research company’s stock valued at $961,000 after buying an additional 519 shares during the period. CFO4Life Group LLC lifted its position in Amgen by 6.5% in the 2nd quarter. CFO4Life Group LLC now owns 4,595 shares of the medical research company’s stock valued at $848,000 after acquiring an additional 279 shares in the last quarter. Oak Asset Management LLC lifted its position in Amgen by 17.2% in the 2nd quarter. Oak Asset Management LLC now owns 48,676 shares of the medical research company’s stock valued at $8,985,000 after acquiring an additional 7,142 shares in the last quarter. Assetmark Inc. lifted its position in Amgen by 3.1% in the 2nd quarter. Assetmark Inc. now owns 93,231 shares of the medical research company’s stock valued at $17,210,000 after acquiring an additional 2,840 shares in the last quarter. Finally, Altman Advisors Inc. lifted its position in Amgen by 36.8% in the 2nd quarter. Altman Advisors Inc. now owns 16,796 shares of the medical research company’s stock valued at $2,422,000 after acquiring an additional 4,522 shares in the last quarter. Hedge funds and other institutional investors own 76.94% of the company’s stock.

Shares of NASDAQ:AMGN opened at $191.44 on Friday. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19. The stock has a market cap of $126.02 billion, a price-to-earnings ratio of 15.22, a price-to-earnings-growth ratio of 2.05 and a beta of 1.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. During the same period in the previous year, the firm posted $3.27 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, equities analysts forecast that Amgen, Inc. will post 14.24 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a dividend of $1.45 per share. This is a boost from Amgen’s previous quarterly dividend of $1.32. This represents a $5.80 annualized dividend and a yield of 3.03%. Amgen’s payout ratio is 41.97%.

In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $202.88, for a total transaction of $360,517.76. Following the sale, the senior vice president now directly owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.19% of the company’s stock.

Several equities research analysts recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $220.00 price objective on shares of Amgen in a research report on Tuesday. Barclays reaffirmed a “neutral” rating and issued a $195.00 price objective on shares of Amgen in a research report on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $223.00 price objective on shares of Amgen in a research report on Tuesday. JPMorgan Chase & Co. set a $192.00 price objective on shares of Amgen and gave the company a “neutral” rating in a research report on Tuesday. Finally, Royal Bank of Canada reaffirmed a “neutral” rating and issued a $182.00 price objective on shares of Amgen in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $205.68.

TRADEMARK VIOLATION WARNING: “Ancora Advisors LLC Purchases 509 Shares of Amgen, Inc. (AMGN)” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/12/08/ancora-advisors-llc-purchases-509-shares-of-amgen-inc-amgn.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

See Also: Catch-Up Contributions

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.